- Title: Subtitle
- Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
- Creators
- Won-Seog Kim - 1Samsung Medical Center, Center for Hematologic Malignancy, Seoul, Korea, Republic of (South)Tae Min Kim - Seoul National University HospitalSeok-Goo Cho - The Catholic University of Korea Seoul St. Mary's HospitalIsidro Jarque - Hospital Universitari i Politècnic La FeElżbieta Iskierka-Jażdżewska - Copernicus Memorial HospitalMichelle Limei Poon - National University HospitalH. Miles Prince - The University of MelbourneSung Yong Oh - Dong-A University HospitalFrancesca Lim - Singapore General HospitalCecilia Carpio - Universitat Autònoma de BarcelonaTran-Der Tan - Koo Foundation Sun Yat-Sen Cancer CenterSabarish Ayyappan - University of IowaAntonio Gutierrez - Hospital Universitario Son EspasesJingjin Li - Regeneron (United States)Melanie Ufkin - Regeneron (United States)Min Zhu - Regeneron (United States)Aafia Chaudhry - Regeneron (United States)Hesham Mohamed - Regeneron (United States)Srikanth R. Ambati - Regeneron (United States)Jan Walewski - Państwowy Instytut Badawczy
- Resource Type
- Abstract
- Publication Details
- Blood, Vol.140(Supplement 1), pp.1070-1071
- DOI
- 10.1182/blood-2022-158406
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Language
- English
- Date published
- 11/15/2022
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984361722402771
Abstract
Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
Blood, Vol.140(Supplement 1), pp.1070-1071
11/15/2022
DOI: 10.1182/blood-2022-158406
Details
Metrics
88 Record Views